2-(哌嗪-1-基)乙酸水合物 | 667462-09-1

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 中文名称: 2-(哌嗪-1-基)乙酸水合物
• 中文别名: 2-(哌嗪-1-基)-乙酸水合物；2-(1-哌嗪基)乙酸一水合物
• 英文名称: 2-(Piperazin-1-yl)acetic acid hydrate
• 英文别名: 2-piperazin-1-ylacetic acid;hydrate
• CAS: 667462-09-1
• 化学式: C6H14N2O3
• 分子量: 162.19
• InChiKey: XQZJPHXZNNGXHO-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -1.85
• 重原子数：
  11
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.83
• 拓扑面积：
  53.6
• 氢给体数：
  3
• 氢受体数：
  5

文献信息

• Anti-hypertensive molecules and process for preparation thereof
  申请人：Pasha Santosh

  公开号：US20050032709A1

  公开（公告）日：2005-02-10

  The present invention relates to novel anti-hypertensive molecules. The present invention also provides a process for the preparation of novel antihypertensive molecules. The present invention particularly relates to the preparation of novel Agotensin Converting Enzyme Inhibitors (ACEI) with prolonged activity. ACE inhibitors play an important role in Renin-Angiotensin-Aldosteron system (RAAS) by inhibiting the activity of Angiotensin Converting Enzyme (ACE) and therefore are used to regulate blood pressure. ACE inhibitors synthesized by the process of present invention have a peptide moiety and nonpeptide moiety. ACE inhibitors, synthesized by this present invention, show enhanced bioavailability and fewer side effects.

  本发明涉及新型抗高血压分子。本发明还提供了一种制备新型抗高血压分子的工艺。本发明尤其涉及制备具有延长活性的新型激动素转换酶抑制剂（ACEI）。ACE 抑制剂通过抑制血管紧张素转换酶（ACE）的活性，在肾素-血管紧张素-醛固酮系统（RAAS）中发挥重要作用，因此用于调节血压。通过本发明工艺合成的 ACE 抑制剂具有肽基和非肽基。本发明合成的 ACE 抑制剂生物利用度提高，副作用减少。
• LOW AFFINITY SCREENING METHOD
  申请人：Graffinity Pharmaceuticals Aktiengesellschaft

  公开号：EP1360489A1

  公开（公告）日：2003-11-12
• US7335644B2
  申请人：——

  公开号：US7335644B2

  公开（公告）日：2008-02-26
• [EN] LOW AFFINITY SCREENING METHOD<br/>[FR] PROCEDE DE CRIBLAGE DES FAIBLES AFFINITES
  申请人：GRAFFINITY PHARM DESIGN GMBH

  公开号：WO2002063299A1

  公开（公告）日：2002-08-15

  A parallel high throughput screening method on a solid support is disclosed that allows the detection of low affinity binding partners, comprising the steps of:(a) providing a library of different ligands;(b) forming a binding matrix comprising the ligands on a solid support by immobilising said ligands on the support; (c) contacting a target of interest with said binding matrix; (d) parallely determining a binding value of the ligand/target interaction for each type of ligand comprised in the binding matrix; (e) selecting those ligands the binding value of which in an immobilised state towards the target exceeds a predetermined threshold; (f) evaluating the affinity of each of the ligands selected in step (e) in a non-immobilised state towards the target; (g) identifying at least one ligand of step (f) as low affinity binding ligand.
• [EN] ANTI-HYPERTENSIVE MOLECULES AND PROCESS FOR PREPARATION THEREOF<br/>[FR] MOLECULES CONTRE L'HYPERTENSION ET LEUR PROCEDE DE PREPARATION
  申请人：COUNCIL SCIENT IND RES

  公开号：WO2004087743A2

  公开（公告）日：2004-10-14

  The present invention relates to novel anti-hypertensive molecules. The present invention also provides a process for the preparation of novel antihypertensive molecules. The present invention particularly relates to the preparation of novel Angiotensin Converting Enzyme Inhibitors (ACEI) with prolonged activity. ACE inhibitors play an important role in Renin-Angiotensin-Aldosteron system (RAAS) by inhibiting the activity of Angiotensin Converting Enzyme (ACE) and therefore are used to regulate blood pressure. ACE inhibitors synthesized by the process of present invention have a peptide moiety and nonpeptide moiety. ACE inhibitors, synthesized by this present invention, show enhanced bioavailability and fewer side effects.